The Effects of Glucagon on Hepatic Metabolism
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 60
- Registration Number
- NCT05500586
- Locations
- πΊπΈ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Phase 2
Recruiting
- Conditions
- Type2diabetes
- Interventions
- Behavioral: Caloric RestrictionDrug: Hyperglycemic clamp
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 20
- Registration Number
- NCT05499702
- Locations
- πΊπΈ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes
Phase 3
Completed
- Conditions
- HealthyType 2 Diabetes
- Interventions
- Biological: Exendin-9,39 + Intralipid/HeparinBiological: SalineBiological: Exendin-9,39Biological: Saline + Intralipid/Heparin
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 23
- Registration Number
- NCT04466618
- Locations
- πΊπΈ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
Phase 3
Recruiting
- Conditions
- Healthy
- Interventions
- Other: SalineBiological: Exendin-9,39
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 40
- Registration Number
- NCT04466566
- Locations
- πΊπΈ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Drug: 0.4mU Insulin followed by withdrawal period followed by 0.8mU studyDrug: 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 12
- Registration Number
- NCT04461015
- Locations
- πΊπΈ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion
Phase 3
Completed
- Conditions
- Healthy
- Interventions
- Biological: Exendin-9,39Other: Saline
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 11
- Registration Number
- NCT04459338
- Locations
- πΊπΈ
Mayo Clinic in Rochester, Rochester, Minnesota, United States
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
Early Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Exendin 9,39Drug: Placebo
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 12
- Registration Number
- NCT01843855
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
Early Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: PlaceboDrug: Exendin 9, 39
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 20
- Registration Number
- NCT01843881
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
Dose-response Study of Exendin-9,39 on Glucose Metabolism
Phase 1
Completed
- Conditions
- Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
- Interventions
- Drug: saline infusionDrug: GLP-1-9,36 infusionDrug: Exendin-9,39 at low doseDrug: Exendin-9,39 at high dose
- First Posted Date
- 2010-10-11
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- Adrian Vella
- Target Recruit Count
- 11
- Registration Number
- NCT01218633
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
Β© Copyright 2025. All Rights Reserved by MedPath